ERBB2 and breast carcinoma: T-DM1 + Palbociclib: In a phase 1b study initiated in 2014 (NCT01976169), researchers investigated the combination of T-DM1 with Palbociclib (PD-0332991) in patients with recurrent or metastatic HER2-positive breast cancer.